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1. The enzymes of glutamine metabolism 
1 .I. Glutaminase isoenzymes (EC 3.5.1.2) 
In his paper, entitled, ‘The synthesis of glutamine 
from glutamjc acid and ammonia, and the enzymic 
hydrolysis of glutamine in animal tissues’ published 
4.5 years ago [l], H. A. Krebs perceptively recognized: 
‘there are at least two types of glutaminase distin- 
guishable by their pH optima and their inhibitions 
by glutamic acid (‘brain type’ and ‘liver’ type’)‘. 
The mitochondrial ‘phosphate-dependent’ isoen- 
zymes are considered to be the true glutaminases. 
Liver, and possibly lung, possess the ‘liver-type’ 
isoenzyme; all other tissues, including brain and lung, 
have the ‘kidney-type’ [2]. The two are distinguish- 
able on the basis of Pi requirement (the ‘liver-type’ 
requires a low concentration for activation, the ‘kid- 
ney-type’ a high concentration), pH optima, affinity 
for glutamine, reactions with activators and inhibitors 
[2] and inhibition by glutamate [I]. The tissue distri- 
bution of glutaminase activity reported by different 
workers is not identical, but highest activity is present 
in kidney, brain and possibly small intestine, with 
much lower activity in liver and other tissues [2,3]. 
The liver-type enzyme appears in rat liver during 
the 48 h before birth, reaching almost adult activity 
within 6 days [4]. Foetal liver contains the kidney- 
type enzyme. Its activity parallels the amount of 
haematopoietic, not the parenchymal, tissue. Although 
the phosphate requirement of the liver enzyme is 
low (Km 2.8 mM) the Km for glutamine is very high: 
28 mM [5] to 42 mM [2]. Observations that low con- 
centrations of glutamine are not metabolized by 
perfused liver [6] or hepatocytes [7] led to the sug- 
gestion that the liver enzyme does not degrade gluta- 
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mine under physiological conditions [7]. Now a num- 
ber of activators have been identified, and the picture 
is changed but by no means clear. 
So far, increased flux through glutaminase has 
been observed in the presence of the following: NH: 
[X-13], HC05 [13,14], glucagon [12], dibutryryl- 
CAMP [ 141, L-leucine [ 141, L-isoleucine , L-valine 
and NHzOH [15]. The relative effectiveness of these 
compounds is very dependent on the conditions. In 
isolated hepatocytes their effects on glutamine 
removal decrease in the order NH’, > HCO; > dibu- 
tyryl-CAMP > branched-chain amino acids [ 151, 
whereas in the perfused liver Haussinger et al. [ 161 
find no effect of HCO:, presumably because a short 
exposure to 3 mM NH4C1 had pre-activated glutamin- 
ase in their experiments. Only HCO, NH: and ATP 
[ 131 are effective in mitochondrial preparations. 
However, activation by glucagon persists in mitochon- 
dria isolated from glucagon-treated rats [ 171. Activa- 
tion by NH: or HCO; is greatest in the presence of 
phosphate and ATP [ 131, and both decrease the 
requirement for phosphate [ 181 and the Km for 
glutamine (see [ 131). The acceleration of glutamine 
metabolism by branched-chain amino acids in the 
intact cell may be an indirect effect on glutaminase. 
None of these activators has been tested with the 
solubilized enzyme. It is also worth remembering that 
the activity in liver [2,3] was determined before the 
allosteric nature of glutaminase was known. This 
basal activity is increased about 20-fold by the pres- 
ence of HCO, NH: and ATP [ 13,151. 
In surveying the literature on glutaminases it is 
very difficult to obtain a consistent picture. The 
‘phosphate-dependent’ glutaminases of liver, kidney 
and brain described by Katunuma et al. [ 191 are all 
different, and the liver enzyme, in regard to heat 
inactivation, pH optimum and inhibition bymercurials, 
does not correspond with the liver enzyme described 
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by Horowitz and Knox [2]. Recently, on the basis of 
inhibition by p-mercuribenzoate, two distinct phos- 
phate-dependent mitochondrial glutaminases are 
reported to be present in both pig kidney cortex and 
rat brain [20], again contrary to the findings of 
Horowitz and Knox [2]. 
If one takes the view that the regulatory properties 
of an enzyme will reflect its role in the parent tissue, 
then it makes good physiological sense that the liver 
glutaminase should be unique and responsive to 
indicators of dietary state. There are possible expla- 
nations for some of the apparent~differences in 
results from different laboratories: 
(i) The liver glutaminase is associated with the inner 
mitochondrial membrane and exhibits the phe- 
nomenon of latency, in that activity is increased 
on incubation of mitochondria in hypotonic 
media [15,21,23]. 
(ii) The kinetic properties of the enzyme are altered 
by its association with the membrane; the Km for 
glutamine of the membrane-bound form is lower 
(6 mM) than that of the solubilized form (2 1 mM) 
PI. 
(iii) A factor that has not been taken into account 
has been the extent to which the various acti- 
vators bring about mitochondrial swelling (see 
[22,231x 
(iv) The temperature at which the activators are stud- 
ied affects the results [23]. 
Temperature can be ruled out as a variable in vivo, 
but variations in mitochondrial volume cannot. There 
seems to be no information available. It would be 
interesting to know whether the phenomenon of 
latency, in the context of mitochondrial swelling, has 
any meaning in the intracellular environment. 
The ‘kidney-type’ glutaminase, as already men- 
tioned, is widely distributed and has a very high phos- 
phate requirement in vitro; Km 74 mM [2]. The 
enzyme of brain and kidney has been most studied. 
The Km for glutamine of the solubilized enzyme 
varies, depending on the phosphate concentration 
[24] and, as for the liver enzyme, is higher for the 
soluble than for the bound form. The lowest Km is 
obtained in mitochondria in a hypotonic medium; 
1.5 mM [25]. A characteristic of the kidney- or 
brain-type enzyme, first observed by Krebs [ 11, is 
that it is inhibited by glutamate. The enzyme is acti- 
vated by riboflavin S-phosphate and other phosphate 
esters [26], ATP, GTP, ITP, acetate, and di- and tri- 
carboxylic acids [24,27]. Cyclic AMP and GMP are 
inhibitors [24]. The physiological function of these 
modifiers is not known. 
1.2. Glutamine 2-oxoacid aminotransferase (EC 
2.6.1.15) 
The aminotransferase pathway for glutamine 
degradation may function in some tissues under cer- 
tain conditions. The combined reactions of the 
aminotransferase and w-amidase (EC 3 S. 1.3) were 
formerly known as ‘glutaminase II’. So far two forms 
of the aminotransferase have been described, a kidney- 
type and a liver-type, both of which exist as a mito- 
chondrial and cytosolic isoenzyme. All four isoen- 
zymes are found in different proportions in liver and 
kidney [28]. The specificity for the 2-oxoacid accep- 
tor is different in the two tissues. In hepatocytes 
glutamine at physiological plasma concentration (0.5 
mM) is readily metabolized in the presence of 2-0x0- 
4-methylthiobutyrate (the 2-oxoacid analogue of 
methionine) and to a lesser extent in the presence of 
phenylpyruvate, whereas pyruvate has no effect [7]. 
In kidney, which is reported to contain a higher activ- 
ity of the aminotransferase than liver [29], neither 
phenylpyruvate nor 2-oxo-4-methylthiobutyrate is 
effective in increasing glutamine metabolism [30]. 
The aminotransferase is not specific for glutamine; 
methionine can replace glutamine [31]. We [32] find 
that this enzyme and the branched-chain 2-oxoacid 
dehydrogenase are involved in the degradation of 
methionine via the transamination pathway in the 
liver [33]. 
The glutamine aminotransferase is very important 
for the amination of 2.oxoacid analogues of essential 
amino acids [34] when administered clinically as pro- 
tein-sparing agents (see [35]) in the treatment of 
uraemia or inborn errors of the urea cycle. Cooper 
and Meister [28] suggest hat it may function under 
normal physiological conditions to re-aminate small 
amounts of 2-oxoacids formed during normal metab- 
olism of essential amino acids. This would, in effect, 
be a salvage function. 
1.3. y-Glutamyltranspeptidase (EC 2.3.2.2) 
Formerly known as ‘phosphate-independent’ glu- 
taminase, it is not a true glutaminase. Its glutaminase 
activity is stimulated by maleate [36]. r-Glutamyl- 
transferase is the Enzyme Commission-recommended 
trivial name, but this activity is a property of several 
enzymes (see [37]). The transpeptidase was post- 
ulated as the amino acid-transporting enzyme in 
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the ‘Meister cycle’ [38]. Its location in outer cell 
membranes, such as the brush border membrane of 
kidney proximal tubules [39] and intestinal mucosa 
[40] and in the plasma membrane of liver [41] and 
other tissues, is in keeping with a transport function. 
However, recently an association with glutathione 
metabolism has been proposed in that glutathione in 
the glomerular filtrate is hydrolysed by the transpep- 
tidase with recovery of the components [42-451. In 
addition the enzyme catalyses the oxidation of 
glutathione to glutathione disulphide [46]. These 
functions do not rule out the possibility that the 
enzyme is also involved in ammo acid transport. In 
lactating mammary gland, for example, which removes 
large amounts of amino acids from the circulation, 
and in which tissue there is a very large increase in 
y-glutamyltranspeptidase activity during the lactogenic 
cycle [47]. 
1.4. Glutamine synthetase (EC 6.3.*1.2) 
The enzyme is present in most tissues, but in a 
separate compartment from glutaminase; in liver it 
is in soluble fraction, but in brain is largely membrane 
bound (see [48]). There are various reports on the 
tissue distribution [49-521, and on the distribution 
within heterogeneous tissues as, for example, the 
nephron of the rat [53]. Little is known of the regula- 
tion of the activity of the enzyme in situ. In the intact 
liver cell in vitro the high capacity for glutamine 
synthesis is not expressed [7,54]. On the other hand, 
perfused rat kidney forms glutamine [55] although 
the assayable enzyme activity is much lower than in 
liver. For details of the complex kinetic properties of 
glutamine synthetase, see Meister [56] and Deuel et 
al. [57]. 
1.5. Other reactions involving glutamine 
Welbourne [SS] has studied a y-glutamyltransferase 
in rat kidney that is distinct from y-glutamyltranspep- 
tidase. Like glutamine synthetase, it is not present in 
dog or human kidney [59], which suggests a common 
identity. Alternatively it may be the y-glutamyltrans- 
ferase described by Herzfeld and Estes [52]. In either 
case its physiological function is not settled. 
Other reactions involving glutamine which are not 
considered here include the formation of amino 
sugars (EC 5.3.1.191, asparagine (EC 6.3.5.4), purine 
(EC2.4.2.14andEC6.3.5.3),pyrimidine(EC6.3.5.5), 
NAD (EC 6.3.5.1) and incorporation into proteins. 
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2. Glutamine metabolism in viva 
2.1 . Utilization 
Under normal physiological conditions the small 
intestine is the main glutamine-utilizing tissue; others 
are quantitatively far less important (see section 3). For 
example, glutamine is an oxidative fuel of synapto- 
somes and a precursor of both excitatory (glutamate 
and aspartate) and of inhibitory (y-aminobutyric 
acid) neurotransmitters [60], yet the metabolism of 
the brain, as measured by arteriovenous differences, 
appears to result in a net glutamine synthesis [54,61, 
621. 
There are conditions (metabolic acidosis and lacta- 
tion) during which the kidney and mammary gland, 
respectively, make extra demands on the glutamine 
supply. In normal acid-base balance there is no 
uptake of glutamine by rat kidney in vivo [7,63,64], 
essentially confirming earlier work of Pitts [65] who 
found that glutamine hydrolysis was almost exactly 
balanced by glutamine synthesis in the non-acidotic 
rat kidney. The uneven distribution of glutaminase 
and glutamine synthetase along the nephron [53] 
makes cycling feasible in the kidney of animals, like 
rat, that possess glutamine synthetase. By contrast, 
all rat kidney preparations in vitro, including the 
isolated perfused kidney, catabolize glutamine at the 
concentration found in plasma (0.5 mM). Therefore 
some important physiological regulatory mechanisms 
are lost on exposure of the tissue to an artificial 
‘plasma’. This should be borne in mind when using 
kidney preparations in vitro to study the mechanism 
of adaptation to metabolic acidosis. How glutamine 
degradation is ‘switched-on’ in acidosis is not settled, 
in spite of the vast amount of research. One simple 
explanation for many of the apparently conflicting 
observations is that an increase in mitochondrial vol- 
ume somehow occurs in acidosis, leading to an activa- 
tion of the latent glutaminase (see section 1.2). Many 
of the well-established metabolic events would then 
automatically occur. Ammonia is released from the 
normal rat kidney, mainly into renal venous blood, 
even though no net removal of glutamine or other 
amino acid is sufficient to account for it (see [64]). 
Possibly the components of glutathione, reabsorbed 
after hydrolysis by y-glutamyltranspeptidase in the 
lumen (see section 1.3), are the precursors of this 
ammonia. 
In the case of the lactating mammary gland large 
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amounts of amino acids are removed from the arterial 
plasma for milk protein synthesis. However, the 
amounts of glutamine removed are too great to be 
used only for casein synthesis [66], and glutamine 
appears to be used also as a metabolic fuel (see section 
3). The oxidation of glutamine is puzzling in view of 
the report that glutaminase activity is extremely low 
[67]. On the other hand, y-glutamyltranspeptidase 
appears and reaches high activity during the lactogenic 
cycle [47]. This raises again the question as to whether 
y-glutamyltranspeptidase is involved in amino acid 
transport in certain tissues. 
2.2. Production 
Skeletal muscle has been taken to be the most 
important source of endogenous glutamine since the 
Cahill group [68] found that glutamine and alanine 
together account for about 50% of amino acids 
released into venous blood from the human forearm 
after an overnight fast. This discovery prompted 
research to determine whether the carbon skeleton 
of the alanine released is also derived from the catab- 
olism of other amino acids (which would lead to a 
net synthesis of glucose in starvation) or from carbo- 
hydrate (which would not). As branched-chain amino 
acids constitute about 22% of the total amino acids of 
protein and as they, unlike other amino acids, are not 
metabolized by the liver, they have been the focus of 
attention. There is still no general agreement on the 
source of the carbon. A number of groups conclude 
that branched-chain amino acids are important pre- 
cursors [69-731; others that the pyruvate arises from 
glycolysis, while the carbon skeleton of glutamine is 
derived from other amino acids [74,75]. However, 
measurements of arteriovenous differences across the 
hindlimb of the rat show that large amounts of 2-0~0. 
acids, formed by transamination of branched-chain 
amino acids are released from skeletal muscle, and 
removed by the liver [76]. This means that the contri- 
bution of the carbon skeleton of branched-chain 
amino acids to the formation of alanine or glutamine 
must be re-assessed, at least in the rat. The situation 
in man is different, because there is little or no release 
of branched-chain 2.oxoacids by skeletal muscle [77]. 
2.3. Role of the liver 
The liver appears to function as either a glutamine- 
synthesizing or a glutamine-utilizing tissue, depending 
on the physiological state of the rat. In starved [78], 
high carbohydrate fed [79] or normal fed [7] there 
appears to be glutamine output, but livers of rats fed 
a high protein diet remove glutamine 179,801. These 
data are based on arteriovenous difference measure- 
ments and should be interpreted with caution because 
of the problem of the relative contributions of the 
arterial and portal blood supplies. In general, assump- 
tions have been made as to flow rate. The findings in 
vivo make more physiological sense than the experi- 
ments in vitro that suggested that neither glutaminase 
nor glutamine synthetase is functional in the intact 
liver cell (see section 1.2,1 S). The effect of the high 
protein diet can be explained by increased flux of 
ammonia and/or amino acids into the mitochondria, 
and the presence of glucagon which will serve to acti- 
vate liver glutaminase (see section 1.2). The signal for 
glutamine synthesis is not known. Activation of 
liver glutaminase by ammonia provides an explana- 
tion for the observation, unexpected at the time, that 
injection of NH&l into rats decreases the concentra- 
tion of glutamine in the liver [8 I]. For the same 
reason NH4C1 should not be used in future to induce 
metabolic acidosis for the study of how the extra- 
renal tissues meet the demands of the kidney for 
glutamine. Activation of liver glutaminase by NG 
will override the normal response of the liver and, 
indirectly, possibly that of other tissues. These con- 
clusions are, however, made on the assumption that 
increased flwc of NH; into the mitochondrion is asso- 
ciated with an increased concentration at the site of 
glutaminase. While this is probably true after a load 
of NH&l, the urea cycle may be active enough to 
prevent it occurring by dietary means. One should 
also remember that ammonia is continuously released 
into the portal vein in all physiological states as a 
result of glutamine metabolism in the small intestine 
(see section 3), so that there is continuous flux of 
ammonia into liver mitochondria. 
3. Glutamine as a respiratory fuel 
A number of tissues, including kidney [82], reticu- 
locytes [83], synaptosomes [60], lactating mammary 
gland [84], small intestine [85,86], fibroblasts [87], 
lens [88], oocytes [89] and tumour cells (see [90]) 
can oxidize glutamine. In foetal rat liver, because of 
its haematopoietic tissue content and because Of the 
properties of the foetal liver glutaminase [4], gluta- 
mine is probably a very important respiratory sub- 
strate. Thus the high phosphate requirement of the 
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‘kidney-type’ glutaminase (see section 1 .l) does not 
seem to be necessary for the enzyme in situ. 
The quantitative contribution of glutamine oxida- 
tion in vivo has been established only for the small 
intestine, in which the mucosa was identified as the 
site of oxidation, and arterial blood (as opposed to 
the lumen) as the main source of glutamine [9 I]. In 
this tissue arterial glutamine is a more important 
respiratory fuel than is ghrcose in both fed and 
starved rats [92,93]. In the fed state oxidation of 
arterial glucose accounts for only about 10% of the 
02 uptake, and 97% of luminal glucose is transported 
across the tissue without undergoing metabolism. 
Arterial glutamine, on the other hand, can account 
for 38% of the total O2 uptake, and luminal gluta- 
mine, glutamate and aspartate a further 39%, a total 
of 77% [93]. Major products other than COZ and 
ammonia, are alanine, citrulline, and proline [91]. 
The synthesis of citrulline from glutamine is interest- 
ing from the nutritional point of view, because it 
provides an explanation as to why arginine is not an 
essential amino acid in the adult. The amounts of 
alanine and ammonia formed from glutamine, gluta- 
mate and aspartate are so great that they can account 
for about 6% of the urea nitrogen excreted [93]. 
These experiments in vivo illustrate the limitations of 
other intestinal preparations, especially of the iso- 
lated enterocyte, which can provide no information 
on the relative contributions of luminal and arterial 
substrates. In isolated enterocytes glucose is the most 
readily oxidized substrate, there is a very high rate of 
aerobic glycolysis, glutamate is a major endproduct of 
glutamine metabolism, and the amounts of tissue 
used are necessarily small, so that citrulline synthesis 
is too low to be detectable [94]. The work of 
Windmueller and Spaeth has now dispelled the myth 
of the pre-eminence of glucose in the energy metab- 
olism of the small intestine. 
For glutamine to be completely oxidized, acetyl- 
CoA must be formed via pyruvate from malate or 
oxaloacetate. Possible reactions are oxaloacetate 
decarboxylase (EC 4.1 .1.3), phosphoenolpyruvate 
carboxykinase (EC 4.1 .1.32) plus pyruvate kinase 
(EC 2.7.1.40) NADPlinked malic enzyme (EC 1.1.1. 
40) or NAD(P)-linked malic enzyme. Of these PEP 
carboxykinase plus pyruvate kinase is least likely 
because mercaptopicolinate, an inhibitor of PEP 
carboxykinase [95,96] has no effect on the oxida- 
tion of glutamine in the small intestine or in rat 
kidney tubules [97,98]. Watford et al. [98] came to 
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the conclusion that the cytosolic NADP-linked malic 
enzyme was the most likely pathway. A mitochondrial 
route would make more physiological sense because it 
would eliminate shuttling of intermediates to and 
from the cytosol; because of this the NAD-linked 
malic enzyme is an attractive possibility. It has been 
reported to be present in mitochondria of rat liver 
and kidney [99], small intestinal mucosa [ 1001 and 
heart [loll. It is interesting that, in spite of the pres- 
ence of all these enzymes in rat liver, complete oxida- 
tion of glutamine does not appear to occur as gluta- 
mine removed by hepatocytes can be accounted for 
as glutamate and glucose [ 141. 
4. Turnover of glutamine 
In order to minimize interconversions, L- [ 1-14C]- 
glutamine has been used to measure turnover. Results 
obtained by the single injection technique agree very 
closely for normal fed rats: 282 + 33 pmol . h-l. 100 
g body wt-’ [62] and 235 f 12 I.tmol . h-l. 100 g 
body wt-’ [102]. The rate obtained by the constant 
infusion technique is lower: 134 ?r 8 pmol . h-’ . 100 
g body wt-’ [62]. Whichever rate is taken, turnover is 
extremely high compared with the glutamine require- 
ments of the main utilizing tissue, the small intestine 
(1.8 mmol/day in a 280 g rat starved overnight) [9 11. 
The discrepancy cannot be explained by cycling 
between glutamine and glutamate because cycling 
would involve no loss of 14C. Protein turnover, which 
amounts to about 4.4 g/day in 100 g rats [ 1031, pro- 
vides the most likely explanation. 
Glutamine turnover is not increased in metabolic 
acidosis [62], which suggests that the demands of the 
kidney are met by decreased utilization in extra-renal 
tissues. In support of this, with one exception [104], 
there is reported to be no increased release of gluta- 
mine from skeletal muscle in acidosis [7,62,105]. But 
the small arteriovenous differences for the normal 
controls make it doubtful whether skeletal muscle 
can supply the glutamine requirement of the small 
intestine. Similar measurements by Ruderman and 
Berger [ 1061, on the other hand, suggest hat gluta- 
mine release is more than adequate. Neither the 
quantitative importance of skeletal muscle as a source 
of glutamine in the rat, nor how the animal copes 
with the increased demand for glutamine in metabolic 
acidosis or lactation, can be taken as settled. It is 
rather surprising to real& that the body pool of 
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glutamine is maintained largely by endogenous syn- 
thesis because, as a result of intestinal metabolism, 
the glutamine concentration in the portal vein, even 
in the fed state, is generally lower than the arterial 
concentration (see [7,62,79,93]). This is also true in 
lactating rats [ 1021 although food intake is increased 
by 300%. The liver may yet prove to play a funda- 
mental regulatory role in glutamine metabolism in 
the rat. 
Acknowledgement 
The author is a member of the External Staff of 
the Medical Research Council. 
References 
[l] Krebs, H. A. (1935) Biochem. J 29,1951-1969. 
[2] Horowitz, M. L. and Knox, W. E. (1968) Enz. Biol. 
Clin. 9,241-255. 
[ 31 Katunuma, N., Katsunuma, T., Towatari, T. and 
Tomino, I. (1973) in: The Enzymes of Glutamine 
Metabolism (Prusiner, S. and Stadtman, E. R. edsj 
pp. 227-258, Academic Press, London, New York. 
[4] Horowitz, M. L. (1969) Biochem,J. 114,65-70. 
[5] Huang, Y. Z. and Knox, W. E. (1976) Enzyme 21, 
408-426. 
[6] Saheki, T. and Katunuma, N. (1975) J. Biochem. 
(Tokyo) 77,659-669. 
[7] Lund, P. and Watford, M. (1976) in: The Urea Cycle 
(Grisolia, S., Baguena, R. and Mayor, F. eds) pp. 
479-488, Wiley, London, New York. 
[8] Charles, R. (1968) PhD Thesis, University of 
Amsterdam. 
(91 Nordmann, R., Petit, M. and Nordmann, J. (1972) 
Biochimie 54,1473-1478. 
[lo] Haussinger, D. and Sies, H. (1975) 10th FEBS Meet; 
Paris, abstr. 1497. 
[ 111 Colombo, J. P., Bachmann, C., Peheim, E. and Beruter, 
J. (1977) Enzyme 22,399-406. 
[12] Joseph, S. and McGivah, J. D. (1978) Biochim. Bio- 
phys. Acta 543, 16-28. 
[ 131 Joseph, S. and McGivan, J. D. (1978) Biochem. J. 
176,837-844. 
[ 141 Baverel, G. and Lund, P. (1979) Biochem. J. 184, 
599-606. 
[ 151 Ashall, F. and Lund, P. (1980) unpublished. 
(161 Haussinger, D., Akerboom, T. P. M. and Sies, H. 
(1980) Hoppe-Seyler’s Z. Physiol. Chem. 361,995-l 001 
[ 171 Lacey, J. H., Bradford, N. M. and McGivan, J. D. 
(1980) Biochem. Sot. Trans. in press. 
[18] McGivan, J. D., Lacey, J. H. and Joseph, S. (1980) 
unpublished. 
[ 191 Katunuma, N., Huzino, A. and Tomino, I. (1967) Adv. 
Enz. Reg. 5,55-69. 
[20] Kvamme, E. and Olsen, B. E. (1979) FEBS Lett. 107, 
33-36. 
[ 211 Joseph, S., McGivan, J. D. and Meijer, A. J. (1980) 
unpublished. 




















Guha, S. R. and Chakravarti, H. S. (1960) Enzymologia 
22,307-317. 
Weil-Malherbe, H. (1972) J. Neurochem. 19, 
2257-2267. 
Kovazevi& Z., Breberina, M., Pavlovi& M. and Bajin, K. 
(1979) Biochim. Biophys. Acta 567, 216-224. 
Weil-Malherbe, H. and Beall, G. D. (1970) J. Neuro- 
them. 17,1101-1103. 
O’Donovan, D. J. and Lotspeich, W. D. (1966) Nature 
212,930-932. 
Cooper, A. J. L. and Meister, A. (1974) J. Biol. Chem. 
249,2554-2561. 
Kupchik, H. Z. and Knox, W. E. (1970) Methods 
Enzymol. 17,951-954. 
Vinay, P. and Lund, P. (1980) unpublished. 
Cooper, A. J. L. and Meister, A. (1972) Biochemistry 
11,661-671. 
Livesey, G. and Lund, P. (1980) Biochem. Sot. Trans. 
in press. 
Mitchell, A. D. and Benevenga, N. J. (1978) J. Nutrit. 
108,67-78. 
Walser, M., Lund, P., Ruderman, N. B. and Coulter, 
A. W. (1973) J. Clin. Invest. 52, 2865~-2877. 
Richards, P. (1978) Clin. Sci. Mol. Med. 54,589-593. 
Tate, S. S. and Meister, A. (1974) Proc. Natl. Acad. 
Sci. USA 71,3329-3333. 
Meister, A. (1975) in: The Medical Clinics of North 
America: Symposium on Renal Metabolism, vol. 59, 
p. 644, W. B. Saunders, Philadelphia, PA. 
Orlowski, M. and Meister, A. (1970) Proc. Natl. 
Acad. Sci. USA 67,1248-1255. 
Glossmann, H. and Neville, D. M. (1972) FEBS Lett. 
19,340-344. 
Greenberg, E., Wollaeger, E. E., Fleisher, G. A. and 
Engstrom,G. W. (1967) Clin. Chim. Acta 16,79-89. 
(411 Smith, R. L. and Peters, T. J. (1978) Biochem. Sot. 
Trans. 6,543-545. 
[42] Elce, J. S. and Broxmeyer, B. (1976) Biochem. J. 153, 
223-232. 
[43] Wendel, A., Heinle, H. and Silbernagl, S. (1978) Curr. 
Prob. Clin. Biochem. 8,73-84. 
[44] Griffith, 0. W. and Meister, A. (197‘9) Proc. Natl. 
Acad. Sci. USA 76,268-272. 
[45] McIntyre, T. M. and Curthoys, N. P. (1979) J. Biol. 
Chem. 254,6499-6504. 
[46] Tate, S. S. and Meister, A. (1979) J. Biol. Chem. 254, 
5573-5575. 
1471 Puente, J., Varas, M. A., Beckhaus, G. and Sapag- 
Hagar, M. (1979) FEBS Lett. 99,215-218. 
[48] Dierks-Ventling, C., Cone, A. L. and Bessman, S. P. 
(1975) Biochem. Med. 13,21&223. 
[49] Wu, C. (1963) Comp. Biochem. Physiol. 8, 335-351. 
[50] Lund, P. (1970) Biochem. J. 118, 35-39. 
K91 
Volume 117, Supplement FEBS LETTERS 25 August 1980 
1511 Chader, G. J. (1971) Arch. Biochem. Biophys. 144, 
657-662. 
1521 Herzfeld, A. and Estes, N. A. (1973) Biochem. J. 133, 
59-66. 
[53] Burch, H. B., Choi, S., McCarthy, W. Z., Wong, P. and 
Lowry, 0. H. (1978) Biochem. Biophys. Res. 
Commun. 82,498-505. 
[54] Lund, P. (1971) Biochem. J. 124,653-660. 
[55] Nishiitsutsuji-Uwo, J. M., Ross, B. D. and Krebs, H. A. 
(1967) Biochem. J. 103,852-862. 
[56] Meister, A. (1974) in: The Enzymes (Bayer, P. D. ed) 
vol 10, pp. 699-754, Academic Press, London, 
New York. 
[57] Deuel, T. F., Louie, M. and Lerner, A. (1978) J. Biol. 
Chem.253,6111-6118. 
[58] Welbourne, T. C. (1978) Curr. Prob. Clin. Biochem. 8, 
201-211. 
[59] Lemieux, G., Baverel, G., Vinay, P. and Wadoux, P. 
(1976) Am. J. Physiol. 231,1068-1073. 
[60] Bradford, H. F. and Ward, H. K. (1976) Brain Res. 
110,115-125. 
[61] Hills, A. G., Reid, E. L. and Kerr, W. D. (1972) Am. 
J. Physiol. 223, 1470-1476. 
[62] Squires, E. J. (1977) MSc Thesis, University of 
Newfoundland. 
[63] Squires, E. J., Hall, D. E. and Brosnan, J. T. (1976) 
Biochem. J. 160,125-128. 
[64] Relman, A. S. and Yablon, S. (1978) Curr. Prob. 
Clin. Biochem. 8,198-200. 
1651 Damian, A. C. and Pitts, R. F. (1970) Am. J. Physiol. 
218,1249-1255. 
[66] Vifia, J. R. and Viiia, J. (1980) personal communica- 
tion. 
[67] Knox, W. E., Linder, M. and Friedell, G. H. (1970) 
Cancer Res. 30,283-287. 
[68] Marliss, E. B., Aoki, T. T., Pozefsky, T., Most, A. S 
and Cahill, G. F. (1971) J. Clin. Invest. 50, 814-817. 
[69] Davis, E. J. and Bremer, J. (1973) Eur. J. Biochem. 
38,86-87. 
[70] Goldstein, L. and Newsholme, E. A. (1976) Biochem. 
J. 154,555-558. 
[ 7 1 ] Garber, A. J., Karl, I. E. and Kipnis, D. M. (1976) J. 
Biol. Chem. 251,836-843. 
[72] Spydevold, 0. (1976) Acta Physiol. Stand. 97, 
273-280. 
[73] Snell, K. and Duff, R. A. (1977) Biochem. J. 162, 
399-403. 
[74] Blackshear, P. J., Holloway, P. A. H. and Alberti, 
K. G. M. M. (1975) Biochem. J. 150,379-387. 
[75] Goldberg, A. L. and Chang, T. W. (1978) Fed. Proc. 
FASEB 37,2301-2307. 
[ 761 Livesey, G. and Lund, P. (1980) Biochem. J. 188, 
705-713. 
[77] Elia, M. and Livesey, G. (1980) personal communi- 
cation. 
[78] Aikawa, T., Matsutaka, H., Yamamoto, H., Okuda, 
T., Ishikawa, E., Kawano, T. and Matsumura, E. 
(1973) J. Biochem. (Tokyo) 74,1003-1017. 
[79] Rem&, C., Demigne, C. and Auf&e, J. (1978) 
Biochem. J. 170,321-329. 
[80] Yamamoto, H., Aikawa,T., Matsutaka, H., Okuda, T. 
and Ishikawa, E. (1974) Am. J. Physiol. 226, 
1428-1433. 
[81] Brosnan, J. T. and Williamson, D. H. (1974) Biochem. 
J. 138,453-462. 
1821 Hird, F. J. R. and Marginson, M. A. (1968) Arch. 
Biochem. Biophys. 127,718-724. 
[83] Rapoport, S., Rost, J. and Schultze, M. (1971) Eur. J. 
Biochem. 23, 166-170. 
[ 841 ViAa, J. R. and Lund, P. (1980) unpublished. 
1851 Finch, L. R. and Hird, F. J. R. (1960) Biochim. 
Biophys. Acta 43, 268-277. 
1861 Neptune, E. M. (1965) Am. J. Physiol. 209,329-332. 
[ 871 Zielke, H. R., Ozand, P. T., Tildon, J. T. Sevdalian, 
D. A. and Cornblath, M. (1976) Proc. Natl. Acad. Sci. 
USA 73,4110-4114. 
[88] Trayhurn, P. and Van Heyningen, R. (1973) Exp. Eye 
Res. 17, 149-154. 
[89] Bae, I.-H. and Foote, R. H. (1975) Exp. Cell Res. 90, 
432-436. 
[90] Reitzer, L. J., Wice, B. M. and Kennell, D. (1979) J. 
Biol. Chem. 254,2669-2676. 
[91] Windmueller, H. G. and Spaeth,A. E. (1974) J. Biol. 
Chem. 249,5070-5079. 
(921 Windmueller, H. G. and Spaeth, A. E. (1978) J. Biol. 
Chem. 253,69-76. 
[93] Windmueller, H. G. and Spaeth, A. E. (1980) J. Biol. 
Chem. 255,107-112. 
[94] Watford, M., Lund, P. and Krebs, H. A. (1979) Bio- 
them. J. 178,589-596. 
[95] Robinson, B. H. and Oei, J. (1975) FEBS Lett. 58, 
12-15. 
[ 961 Kostos, V., Di Tullio, N. W., Rush, J., Cieslinski, L. 
and Saunders, H. L. (1975) Arch. Biochem. Biophys. 
171,459-472. 
[97] Hanson, P. J. and Parsons, D. S. (1977) Biochem. J. 
166,509-519. 
1981 Watford, M., Vinay, P., Lemieux, G. and Gougoux, A. 
(1979) Biochem. Sot. Trans. 7,753-755. 
1991 Sauer, L. A. (1973) Biochem. Biophys. Res. Commun. 
50,524-531. 
[ 1001 Sauer, L. A., Dauchy, R. T. and Nagel, W. 0. (1979) 
Biochem. J. 184,185-188. 
[ 1011 Lin, R. C. and Davis, E. J. (1974) J. Biol. Chem. 249, 
3867-3875. 
[IO21 Viiia, J. R., Lund, P. and Williamson, D. H. (1980) 
unpublished. 
[ 1031 Garlick, P. J., Millward, D. J., James, W. P. T. and 
Waterlow, J. C. (1975) Biochim. Biophys. Acta 414, 
71-84. 
[IO41 S&rock, H., Cha, C.-J. M. and Goldstein, L. (1980) 
Biochem. J. 188,557-560. 
[ 1051 Lemieux, G., Watford, M., Vinay, P. and Gougoux, A. 
(1980) Int. J. Biochem. 12,75-83. 
[106] Ruderman, N. B. and Berger, M. (1974) J. Biol. Chem. 
249,5500-5506. 
K92 
